Analysis of ONAPGO's expected daily cartridge usage and its impact on the implied net annual revenue per patient for 2026 reveals a usage of about one cartridge per day and net revenue ranging between $70,000 and $80,000 per patient. This is supported by company revenue guidance and expanding patient treatment estimates.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
Please quantify expected average daily cartridge usage for ONAPGO and the implied net annual revenue per patient in 2026.
1. Expected Average Daily Cartridge Usage
2. Implied Net Annual Revenue per Patient
The weighted average cost (WAC) price used historically for modeling annual per patient expense is approximately $100,000 per year1.
Given the gross to net adjustments typically observed in specialty products of 20-30%, with Q1 skewed higher due to launch incentives and expected to moderate over the year21, the effective net price per patient per year would likely range between:
The company's 2026 net sales guidance for ONAPGO is $45 million to $70 million for the full year34.
With more than 700 patients in the initiation queue and over 1,800 enrollment forms submitted to date, a conservative estimate of patient numbers treated in 2026 can be derived by dividing expected net revenue by the annual revenue per patient:
| Metric | Value |
|---|---|
| 2026 ONAPGO net sales guidance | $45M to $70M |
| Estimated net revenue/pt/year | ~$70,000 to $80,000 (based on GN adjustment) |
| Implied treated patients (low) | 45,000,000 / 80,000 ≈ ~560 patients |
| Implied treated patients (high) | 70,000,000 / 70,000 ≈ ~1,000 patients |
This patient count range aligns with the company's comments about initiating several hundred patients in early 2026 while clearing backlog56.
| Factor | Estimate | Supporting Details |
|---|---|---|
| Average daily cartridge usage | ~1 cartridge a day (approximate) | "Probably about a cartridge a day, give or take" 1 |
| Annual WAC price per patient | $100,000 per year | Historical modeling basis 1 |
| Expected gross-to-net discount rate | 20% to 30% | Specialty product typical range 21 |
| Implied net annual revenue per patient | $70,000 to $80,000 | Adjusted based on gross-to-net assumptions 12 |
| 2026 ONAPGO net sales guidance | $45 million to $70 million | Full year 2026 guidance 34 |
| Estimated number of treated patients | ~560 to ~1,000 patients | Derived from sales guidance divided by net revenue |
Conclusion:
ONAPGO's expected average daily cartridge usage is about one cartridge per day, resulting in an implied net annual revenue per patient in 2026 of approximately $70,000 to $80,000 after factoring typical specialty pharmaceutical gross-to-net adjustments. Based on the company’s revenue guidance of $45 to $70 million for 2026, this implies treating approximately 560 to 1,000 patients during the year. These estimates reflect early launch data, ongoing patient enrollment, and resolved supply constraints enabling expanded patient access15392.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Wells Fargo expects fourth-quarter 2026 net interest income of about $13 billion, supported by loan and deposit growth, asset repricing, higher securities balances, and rates. The full-year outlook remains $50 billion, plus or minus. Management did not disclose a numerical Q4 markets/non-markets split; its roughly $1.8 billion markets estimate applies to the full year, not the quarter.
Sources used
Research questionWhat are the drivers of expected fourth-quarter net interest income growth, and how should the markets versus non-markets contribution be understood, including the full-year $50 billion outlook and fourth-quarter split?
Answer outline
Cintas raised its FY2027 incremental-margin outlook to 32%–34% and expects results in the range’s upper half, while cautioning that quarterly progress will be uneven. Workday comparisons, a demanding Q4 comparison, energy assumptions, and cost controls are key factors shaping the outlook; guidance also excludes UniFirst-related transaction costs and assumes no further acquisitions.
Sources used
Research questionWhat is the expected cadence of margins for the rest of the year, and are there notable quarterly comparisons or other factors that could affect it?
Answer outline
AutoZone outlines a store-maturation-driven ROIC story, highlighting zero ROIC in the first year and a path to above 20% by year six, with ~15% by year four. The majority of near-term ROIC gains come from UDS customers through faster delivery and expanded inventory, while national accounts offer longer-term upside but without separate ROIC targets disclosed.
Sources used
Research questionWhat did management say about ROIC by commercial segments?
Answer outline
Management attributes the near-term gross-margin pressure to a rapid ramp in custom products, noting that mix is the primary driver of the Q3 margin decline and that the forecast assumes continued custom growth. They expect the broader Data Center mix—anchored by connectivity and other segments—to stabilize margins in Q4, with margins remaining in the existing range into fiscal 2028 despite ongoing custom expansion.
Sources used
Research questionWhat did management say about Data center margin drivers from custom mix?
Answer outline
Walmart explains that price investments are likely to lift traffic in 2H with lagged effects, while ticket dynamics face deflation and regulatory headwinds; OpEx growth of about 7% is mainly driven by depreciation from CapEx and higher self-insurance costs, with timing shifts supporting the back half.
Sources used
Research questionFor price investments, how will they shape comp assumptions from traffic versus ticket in the second half, and what drove the U.S. OpEx growth of about 7%—timing shifts, liability claims, or other factors?
Answer outline
Marmaxx faced execution-related underperformance due to merchandise-mix gaps in stores, particularly for impulse and basic categories, not due to competition. TJX reports cross-functional fixes and systematic planning to prevent recurrence, with early improvements in August and a targeted return to a 2%-3% comp cadence by Q4 as the holiday season nears.
Sources used
Research questionLorraine Hutchinson asks what went wrong at Marmaxx, what steps have been taken to fix it, and when Marmaxx is expected to return to a 2%-3% comp cadence?
Answer outline
SPX Technologies outlines a data center capacity ramp to $1.1 billion, fueled by OlympusMAX throughput and Everest demand, with 2026–2028 incremental contribution shaped by 2027 production ramps and back-half margin improvement driven by volume leverage and Thermolec.
Sources used
Research questionPlease provide color on data center capacity ramp, including why capacity increased to 1.1 billion from 750 million, the incremental contribution in 2026 versus 2027, and how this capacity expansion and tariffs influence expected top-line growth and HVAC margins in the back half?
Answer outline
Carvana frames its rest-of-2026 EBITDA guidance as midyear guardrails, reinforcing a disciplined, historical approach rather than signaling a fundamental pivot. The Q2 results underpin a favorable trajectory with record unit growth and profitability, and management expects sequential improvements into Q3 and Q4 despite near-term inventory and macro headwinds.
Sources used
Research questionWhy issue EBITDA guidance for the rest of 2026 now, and does it signal a change in the business trajectory vs the first half, in terms of sales or profitability?
Answer outline
Performance Food Group outlines a fiscal 2027 EBITDA path supported by growth across Foodservice, Convenience, and Specialty, with the 8%–13% band excluding the 53rd week. Management notes the 53rd week adds roughly 2% to full-year results, while corporate overhead moves in line with segment-driven safety trends, reinforcing a consolidated improvement rather than an outsized corporate swing.
Sources used
Research questionWhat is the segment-by-segment EBITDA outlook for fiscal 2027 and how does corporate overhead factor into the outlook within the 8%–13% EBITDA growth range (excluding the 53rd week)?
Answer outline
Quanta Services outlines a pathway to higher long-term margins anchored in a greater self-perform mix and larger load-center/generation projects, underpinned by a training-driven expansion of the workforce and a reinforcing backlog buildup. The analysis also flags headwinds such as mix/risk, lumpy project timing, and interconnection bottlenecks that could temper near-term gains even as backlog strengthens.
Sources used
Research questionHow do you view long-term margin upside given higher self-perform mix and larger load-center/generation projects, and what could limit that upside?
Answer outline
Investors are reassured by management's clear operational explanation for ramp-up challenges and contractor performance. The discussion ties production progress to free cash flow prospects, reinforcing cash-flow visibility even as ramp-up remains gradual and strategic bottlenecks are addressed.
Sources used
Research questionYeah. Yeah. that is good color?
Answer outline
Howmet Aerospace reports a strong Q2 2026 with a 32.1% EBITDA margin, up 340 bps year over year as EBITDA outpaced revenue growth. Despite a CAM headwind from the April acquisition, the company delivered a 46% incremental flow-through and highlighted segment margin expansion, with additional CAM synergies anticipated in 2027.
Sources used
Research questionWhat specific factors drove the 340 bps year-over-year improvement to Q2 EBITDA margin (32.1%) despite a modest CAM headwind, and how did incremental flow-through of revenue to EBITDA reach 46%?
Answer outline
Dafinchi